Cargando…

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?

SIMPLE SUMMARY: Measurable residual disease (MRD) is emerging as an important prognostic and predictive biomarker in acute myeloid leukemia (AML). However, its use is currently hampered by the disparity and lack of harmonization between the available MRD methodologies. In addition, the current asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pessach, Ilias, Spyropoulos, Theodoros, Lamprianidou, Eleftheria, Kotsianidis, Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454571/ https://www.ncbi.nlm.nih.gov/pubmed/36077826 http://dx.doi.org/10.3390/cancers14174294

Ejemplares similares

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges
por: Riva, Giovanni, et al.
Publicado: (2021)

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
por: Kordella, Chryssoula, et al.
Publicado: (2021)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

Mapping Cell Phenomics with Multiparametric Flow Cytometry Assays
por: Liu, Yang, et al.
Publicado: (2022)

Multiparametric Flow Cytometry-Based Immunophenotyping of Mouse Liver Immune Cells
por: Vanekova, Lenka, et al.
Publicado: (2022)

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
por: Patkar, Nikhil, et al.
Publicado: (2021)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

P706: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
por: Dimitriou, Despoina, et al.
Publicado: (2023)

Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India
por: Dhingra, Gaurav, et al.
Publicado: (2020)

Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry
por: Clichet, Valentin, et al.
Publicado: (2023)

Identification of Immune Cell Components in Breast Tissues by a Multiparametric Flow Cytometry Approach
por: Coppola, Luigi, et al.
Publicado: (2022)

Immune Responses Raised in an Experimental Colon Carcinoma Model Following Oral Administration of Lactobacillus casei
por: Aindelis, Georgios, et al.
Publicado: (2020)

Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting
por: Modvig, S., et al.
Publicado: (2020)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes
por: Mitroulis, Ioannis, et al.
Publicado: (2023)

P834: MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review
por: Teixeira, Alexandra, et al.
Publicado: (2023)

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
por: Hanekamp, Diana, et al.
Publicado: (2021)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia
por: Pophali, Prateek A., et al.
Publicado: (2019)

Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours
por: Ricklefs, Franz L., et al.
Publicado: (2019)

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
por: Röhnert, Maximilian A., et al.
Publicado: (2022)

Application of Multiparametric Flow Cytometry Panels to Study Lymphocyte Subpopulations in Tuberculin-Positive Cattle
por: Manzo-Sandoval, Anabelle, et al.
Publicado: (2023)

Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience
por: Fazio, Francesca, et al.
Publicado: (2023)

CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones
por: Houtsma, Roos, et al.
Publicado: (2021)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

Myeloid Neoplasms with Isolated Isochromosome 17q: a yet to be Defined Entity
por: Lamprianidou, Eleftheria, et al.
Publicado: (2017)

P701: SYSTEMATIC ANALYSIS OF T LYMPHOCYTES IN MYELOID NEOPLASMS
por: Tasis, Athanasios, et al.
Publicado: (2023)

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

Multiparametric Flow Cytometry Using Near-Infrared Fluorescent Proteins Engineered from Bacterial Phytochromes
por: Telford, William G., et al.
Publicado: (2015)

Multiparametric Analysis of Circulating Exosomes and Other Small Extracellular Vesicles by Advanced Imaging Flow Cytometry
por: Mastoridis, Sotiris, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_opshg6o0ke8amna964e34np5tm